Manasi Telang

Manasi Telang

Auto-generated profile, based on publicly available information

Manasi Telang

CSIR-URDIP (Council of Scientific & Industrial Research - Unit for Research & Development of Information Products), S.No. 113 & 114, NCL Estate, Pashan Road, Pune 411008, Maharashtra, India

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in Phytochemistry
Verified
Journal Article
Closed access
MTManasi Telang
Manasi Telang
ASAjay Srinivasan
Ajay Srinivasan
APAparna Patankar
Aparna Patankar
AHAbhay Harsulkar
Abhay Harsulkar
VJVijay Joshi
Vijay Joshi
VGVidya Gupta
Vidya Gupta

25 September 2013 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
MTManasi Telang
Manasi Telang
SDSivakami Dhulap
Sivakami Dhulap
AMAnita Mandhare
Anita Mandhare
RHRajkumar Hirwani
Rajkumar Hirwani
Mangiferin, a natural C-glucoside xanthone [2-C-β-D-glucopyranosyl-1, 3, 6, 7-tetrahydroxyxanthone], is abundantly present in young leaves and stem bark of the mango tree. The xanthonoid structure of mangiferin with C-glycosyl linkage and polyhydroxy components contributes to its free radical-scavenging ability, leading to a potent antioxidant effect as well as multiple biological activities. An extensive search was carried out to collect patent information on mangiferin and its derivatives using various patent databases spanning all priority years to date. The patents claiming therapeutic and cosmetic applications of mangiferin and its derivatives were analyzed in detail. The technology areas covered in this article include metabolic disorders, cosmeceuticals, multiple uses of the same compound, miscellaneous uses, infectious diseases, inflammation, cancer and autoimmune disorders, and neurological disorders. Mangiferin has the potential to modulate multiple molecular targets including nuclear factor-kappa B (NF-κB) signaling and cyclooxygenase-2 (COX-2) protein expression. Mangiferin exhibits antioxidant, antidiabetic, antihyperuricemic, antiviral, anticancer and antiinflammatory activities. The molecular structure of mangiferin fulfils the four Lipinski's requisites reported to favor high bioavailability by oral administration. There is no evidence of adverse side effects of mangiferin so far. Mangiferin could thus be a promising candidate for development of a multipotent drug.

1 May 2005 in Journal of Insect Physiology
Verified
Journal Article
Closed access
MTManasi A. Telang
Manasi A. Telang
AGAshok P. Giri
Ashok P. Giri
MSMohini N. Sainani
Mohini N. Sainani
VGVidya Gupta
Vidya Gupta

1 February 2009 in Gene
Verified
Journal Article
Closed access
MTManasi A. Telang
Manasi A. Telang
AGAshok P. Giri
Ashok P. Giri
PPPrashant S. Pyati
Prashant S. Pyati
VGVidya Gupta
Vidya Gupta
MTMechthild Tegeder
Mechthild Tegeder
VFVincent R. Franceschi
Vincent R. Franceschi

5 June 2017 in World Journal of Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
DDDipti Dapurkar
Dipti Dapurkar
MTManasi Telang
Manasi Telang

7 March 2017 in Recent Patents on Biotechnology
Verified
Journal Article
Closed access
MTManasi Telang
Manasi Telang
MDMitali Dawalbhakta
Mitali Dawalbhakta
Saffron (Crocus sativus L.) has a long history of use as a food additive and a traditional medicine for treating a number of disorders. Prominent bioactives of saffron are crocin, crocetin and safranal. The aim of this study was to carry out an extensive patent search to collect information on saffron bioactives and their derivatives as therapeutic and cosmeceutical agents. All patents related to the area of interest published globally till date have been reviewed. Moreover, a recent synthetic biology approach to cost effective and consistent production of saffron bioactives has been highlighted. A patent search strategy was designed based on keywords and concepts related to Crocus sativus L. and its bioactives- safranal, crocin and crocetin in combination with different patent classification codes relevant to the technology areas. This search strategy was employed to retrieve patents from various patent databases. The patents which focused on therapeutic or cosmetic applications and claimed compositions comprising crocin, crocetin or safranal as the main active component were selected and analysed. Maximum patenting activity was noticed towards the use of these bioactives in the treatment of neurological disorders followed by multiple uses of the same compound, use in treatment of metabolic disorders and use as cosmeceuticals. Interestingly, there were no patent records related to use of these bioactives in treating infectious disorders. Our patent analysis points out the populous and less explored uses of saffron bioactives and areas where there is further scope for research and growth. Recently developed synthetic biology approach is contributory in improving availability, consistency and cost effectiveness of saffron bioactives.